In this segment of "Fault Lines: Business, Reputation, and the Politics Reshaping Pharma," the conversation turns to the broader policy landscape shaping the run-up to the 2026 midterms. Julie Tierney of Leavitt Partners and Maggie Farley of RC Resolve, part of Real Chemistry, join moderator Leslie Isenegger to discuss which policies are likely to move forward and how companies should prepare to communicate if pricing or manufacturing becomes a flashpoint. Farley then shifts the conversation to preparedness, explaining that companies need to start with the stakeholder's mindset rather than the business rationale, connecting decisions to what they mean for patients and employees. She walks through how scenario planning should identify which stakeholders will be affected and which channels will resonate, and why anchoring every message in patient value gives companies solid ground to stand on amid political polarization. Policy, government affairs, and communications teams will come away with a clearer view of which legislative vehicles are most likely to advance, along with practical guidance on preparing stakeholder messaging before a pricing or manufacturing crisis unfolds.